Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-Term, Open-Label, and Single-Arm Study of NRP104 30 mg, 50 mg, or 70 mg Per Day in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00337285 is registered in ClinicalTrials.gov with New River Pharmaceuticals as lead sponsor.

NCT NCT00337285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00337285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-Term, Open-Label, and Single-Arm Study of NRP104 30 mg, 50 mg, or 70 mg Per Day in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Lead sponsor
New River Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2006
Completion date
June 30, 2008
Enrollment
349 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit disorders with hyperactivity, attention deficit hyperactivity disorder, attention deficit hyperactivity disorders